PlexusDx's GLP-Squared Injection (dual semaglutide and tirzepatide) provides enhanced appetite suppression that may better offset steroid effects than single-compound options, at $289/mo month-to-month, or from $249/mo on the 6-month plan
This triagonist approach represents the current frontier of incretin-based pharmacology, combining appetite suppression and insulinotropic effects with hepatic fat oxidation and resting energy expenditure elevation
Processed foods containing oxidized oils, trans fats, and excessive omega-6 fatty acids that promote inflammatory processes and oxidative stress
The potential antiarrhythmic effects of GLP-1RAs provide new perspectives on the management of T2DM and its complications
BPC-157 (the higher-profile half of the so-called Wolverine stack) has a large animal record and almost no human one
Associate Editor(s)-in-Chief: Kiran Singh, M.D